eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2012
vol. 29
 
Share:
Share:

Case reports
Lichen sclerosus mimicking Bowen’s disease

Helena Rotsztejn
,
Ewa Trznadel-Grodzka
,
Tomasz Krawczyk

Postep Derm Alergol 2012; XXIX, 4: 321-323
Online publish date: 2012/09/23
Article file
- Lichen sclerosus.pdf  [0.07 MB]
Get citation
 
 

Introduction

Lichen sclerosus (LS), also known as lichen sclerosus et atrophicus, is a chronic inflammatory skin disease of unclear etiology in which lymphocytes play an important role [1]. There is some evidence that LS is an autoimmune disease [2, 3]. Autoantibodies of IgG to extracellular matrix protein 1 were identified [4]. In some patients, there was an increased prevalence of autoimmune diseases in family members. Moreover, causes of infections may play a role. There is some information about Borrelia burgdorferi infection as a starting point of the lesions of LS. Thyroid diseases may also be important in some cases. Probably the real pathogenesis is multifactorial [5]. Lichen sclerosus is often connected with vitiligo, which may trigger an autoimmune reaction to melanocytes [6].

First symptom s can appear both in children and adults [7]. The lesions are observed on mucosa areas (anogenital region, oral cavity) and on the skin of any part of the body in an isolated or disseminated form. Women are reported to be affected nearly 10 times more often than men. Clinical features are characterized by whitish porcelain-like sclerotic lesions. The typical skin lesions are usually asymptomatic and benign. In contrast, the lesions in the anogenital region are itchy, burning and may sometimes transform into squamous cell carcinoma [3].

Aim

We want to present a non-typical case of lichen sclerosus observed as an inflammatory lesion well demarcated from the surrounding skin mimicking Bowen’s disease.

Case report

The report presents a case of a 54-year-old man.

The patient’s medical and family history of skin diseases was negative. The physical examination, routine blood panels, antinuclear antibodies, thyroid antibodies, hepatitis and borrelia antibody tests were normal. The single, gradually enlarging, inflamed reddish-white, well-demarcated lesion, with an irregular border and scaling surface, 3 cm  6 cm in diameter. It was situated in the scapula area of the back. It was clinically diagnosed as Bowen’s disease because of gradually enlarging, well-demarcated erythematous plaque with an irregular border and scaly surface (Figure 1). The plaque was gradually enlarging from the beginning.

To our surprise, the biopsy showed atrophic changes of the epidermis with hyperkeratosis and complete smoothing in the dermal-epidermis junction. The layer of homogenous tissue under the epidermis varied in the thickness and subepidermal bullas were observed. Moderate infiltration of lymphocytes was seen in the dermis. A histopathological examination showed a bullous variant of LS (Figure 2). The patient gave his written consent.

Discussion

Lichen sclerosus most commonly affects the anogenital region. In the lesions of this localization the cancerogenesis process may develop. It may occur when human papillomavirus infection is present at the same time. Extragenital lesions do not develop into malignancy [5, 6].

Extragenital lichen sclerosus of childhood presenting as erythematous patches was presented by Stavrianeas et al. [8]. Especially the existence of bullous lesions in extragenital LS is rare and has been reported infrequently [9]. Extragenital bullous lesions are generally asymptomatic and localized. Only incidentally bullous and hemorrhagic LS involve the scalp [10]. Kowalewski et al. showed alterations of the basement membrane zone in bullous and non-bullous variants of extragenital LS. In bullous LS, a blister formed below the lamina [11]. Approximately 20% of affected patients have extragenital lesions that present as small ivory, shiny round papules that become atrophic [10]. The lesions may also be a result of radiotherapy [12]. The mechanism of blister formation is unclear. The process of inflammation is suggested [13].

In differential diagnosis psoriasis should be considered because of well-demarcated and scaly lesions. The present case also needed to be distinguished from localized scleroderma because clinical features could be confused with morphea. The presence of bullae in LS is more frequent than in morphea and has a hemorrhagic component [13]. In many cases there is a close relationship between localized scleroderma and LS. Some authors suggest there are different manifestations of the same disease [14, 15].

The diagnosis of lymphocytoma may be considered when a well-demarcated nodular lesion appears after a tick bite. In our patient a serological test did not confirm Borrelia burgdorferi infection.

We showed one of the rare clinical pictures of LS which suggested Bowen’s disease. A histopathological examination is crucial in confirming the diagnosis. In LS the edema and loss of elastic tissue is characteristic.

Topical treatment of LS is often unsatisfactory [16]. Nowadays topical steroids and tacrolimus are commonly used [17]. We applied clobederm ointment twice a day for a month and then once daily for 2 months. A significant improvement was observed. The lesion disappeared in most of its part.

References

 1. Tchórzewski H, Rotsztejn H, Banasik M, et al. The involvement of immunoregulatory T cells in the pathogenesis of lichen sclerosus. Med Sci Monit 2005; 11: CR 39-43.

 2. Howard A, Dean D, Cooper S, et al. Circulating basement membrane zone antibodies are found in lichen sclerosus of the vulva. Austral J Dermatol 2004; 45: 12-5.

 3. Rotsztejn H, Trznadel-Budźko E, Jesionek-Kupnicka D. Langerhans cells in vulvar lichen sclerosus and squamous cell carcinoma. Arch Immunol Ther Exp 2006; 54: 363-6.

 4. Chan JJ, Oyama N, Neill SM, et al. Characterization of IgG autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Exp Dermatol 2004; 29: 499-504.

 5. Meffert JJ, Davis BM, Grimwood RE. Lichen sclerosus. J Am Acad Derm 1995; 32: 393-416.

 6. Carlson A, Grabowski R, Xiao CM, et al. Possible mechanisms of hypopigmentation in lichen sclerosus. Am J Dermopathol 2004; 24: 97-107.

 7. Eichenfield LF, Honig PJ. Blistering disorders in childhood. Pediatr Clin North Am 1991; 38: 959-76.

 8. Stavrianeas NG, Katoulis AC, Kanelleas AI, et al. Extragenital lichen sclerosus of childhood presenting as erythematous patches. Indian J Dermatol Venereol Leprol 2008; 74: 59-60.

 9. Guerriero C, Manco S, Paradisi S, et al. Extragenital lichen sclerosus and atrophicus treated with topical steroids and retinoids in a child with vitiligo. Int J Immunopathol Pharmacol 2008; 21: 757-9.

10. Marren P, De Berker D, Millard P, Wojnarowska F. Bullous and haemorrhagic lichen sclerosus with scalp involvement. Clin Exp Dermatol 1992; 17: 354-6.

11. Kowalewski C, Kozlowska A, Zawadzka M, et al. Alterations of basement membrane zone in bullous and non-bullous variants of extragenital lichen sclerosus. Am J Dermatopathol 2004; 26: 96-101.

12. Tournillac I, Dandurand M, Guillot B. Bullous lichen sclerosus after radiotherapy. Ann Dermatol Venereol 1998; 125: 121-3.

13. Rencic A, Goyal S, Mofid M, et al. Bullous lesions in scleroderma. Int J Dermatol 2002; 41: 335-9.

14. Hallel-Halevy D, Grunwald MH, Yerushalmi J, Halevy S. Bullous lichen sclerosus et atrophicus. J Am Acad Dermatol 1998; 39: 500-1.

15. Ristić B, Divic J, Belic LJ, Zdelar D. Bullous lichen sclerosus atrophicus. JEADV 2004; 18: 108-9.

16. Klein LE, Cohen SR, Weinstein M. Bullous lichen sclerosus

et atrophicus: treatment by tangential excision. J Am Acad Dermatol 1984; 10: 346-50.

17. Wakamatsu J, Yamamoto T, Uchida H, Tsuboi R. Lichen sclerosus et atrophicus of the lip: successful treatment with topical tacrolimus. JEADV 2008; 22: 760-2.
Copyright: © 2012 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.